After receiving approval from both the Senate and the House of Representatives, two pieces of bipartisan US legislation aimed improving education around biosimilars and lowering drug costs are now headed for US president Joe Biden’s consideration.
“Passing these bills in Congress has the potential to lower prescription costs for patients, but also for taxpayers, because taxpayers pay a lot of the bill too,” said Senator Bill Cassidy, as
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?